



# Lumos Diagnostics Holdings Limited



Q4 FY24 Investor Presentation

1 August 2024

[lumosdiagnostics.com](https://lumosdiagnostics.com)

# Disclaimer and Important Information



**This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).**

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at [www.asx.com.au](http://www.asx.com.au).

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

## **Non-IFRS financial measures**

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

# Contents

- 
-  **Company Overview**
  -  **Q4 FY24 Highlights**
  -  **Financials**
  -  **Services Update**
  -  **Product Update**
  -  **Key Strategic Priorities**
  -  **Questions**



# Company Overview

A horizontal bar composed of several colored segments: yellow, grey, cyan, purple, light purple, dark purple, red, and orange.

# Company Overview



Lumos is a developer and manufacturer of connected instrumentation and rapid point-of-care tests for the diagnostics and healthcare industries



## Experienced leadership team

- Led by Doug Ward (CEO/MD) - industry veteran with over 30 years' in diagnostics
- Experienced business/technical/commercial leaders also include Barrie Lambert (CFO); Sacha Dopheide (CTO) & Paul Kase (SVP Commercial Ops)



## Comprehensive & integrated offering

- Concept design, development, clinical, regulatory, commercial production
- Proprietary reader platforms providing connected use in different clinical settings
- Development and manufacturing facility located in Carlsbad, California



## Transformational Hologic agreements

- Strategic relationship with US-based women's health leader Hologic – expanded in January 2024 with two transformative new agreements



## Commercialised proprietary POC diagnostic products

- FebriDx – aid in the diagnosis of bacterial v viral acute respiratory infection
- ViraDx – test for key respiratory infections (COVID/Flu A/B)



# Lumos Service Offering



## 1. Fully-integrated—from design to manufacturing



## 2. Proprietary reader platform for use in different settings



## 3. IVD development and manufacturing expertise




## 4. Clinical validation, trial management, and regulatory



# Lumos POC Diagnostic Test Development Engine



Product Concepts



## Q4 FY24 Highlights





# Key Highlights from Q4 FY24



## **Key “Phase 1 Milestone” of the fFN Development Agreement achieved**

*With leading US women’s health company, Hologic - US\$0.4 million milestone payment received*



## **Cash receipts of US\$7.4 million**

*Including US\$5.0 million non-refundable payment from Hologic under the IP Agreement*



## **2<sup>nd</sup> consecutive quarter of positive net cash flows - US\$3.1 million**

*Cash balance at year end - US\$6.5 million*



## **Unaudited revenue of US\$4.3 million**

*Up 8% compared to the prior quarter*



## **Strong Services business growth**

*Revenue was up 21% on Q3, driven by progress on projects with Hologic*



## **Post reporting - Henry Schein**

*Expanded distribution agreements in Australia, New Zealand and Belgium*




# Financials



# Financials - Summary



(US\$ in thousands)



## Q4 FY24 COMMENTARY

- **Unaudited group revenue** of US\$4.3 million for Q4 FY24, up 8% compared with the prior quarter
- **Services business** revenue was US\$4.0 million, with the majority from consulting development services under the fFN Development Agreement and the intellectual property licensing revenue associated with the Hologic IP Agreement.
- **Products** revenue was US\$0.3 million, which was lower than the prior quarter. In line with management expectations, given the US 2023/24 flu season had largely concluded, leading to lower sales of ViraDx and FebriDx in the quarter.
- **Positive net cash generation** for the quarter of US\$3.1 million (operating & investing cash flow, plus lease payments), was an improvement on the US\$2.0 million cash generation in the previous quarter.
- **Cash balance** of US\$6.5 million at year end.

*\*Net cash generation comprised of operating and investing cash flow, plus lease payments.*

# Services Update

A horizontal bar composed of several colored segments: yellow, light blue, dark blue, purple, red, and orange.

# Hologic - Strategic Partnership Update



The Agreements build on previous work conducted by Lumos and Hologic and focus on the development of an improved version of one of Hologic's leading in-market women's health products, including adapting it for use on Lumos' proprietary reader platform

The two agreements are for the development of, and intellectual property rights for, custom reader and point of care technologies.

- The **IP Agreement** provides Hologic with an exclusive license in the field of fetal fibronectin to the Lumos proprietary reader and POC technologies that will be incorporated into the next generation product, under development. IP Agreement was valued at US\$10M in two non-refundable payments; US\$5.0M upon signing US\$5.0M in June 2024, with both payments received.
- **Development Agreement** valued at up to US\$4.7M in payments over an 18-24 month period, dependent on the achievement of specified milestones, outlined below:
  - **Phase 1: Product Definition and Planning** - define the parameters for the product and establish a project plan US\$0.4 million - completed;
  - **Phase 2: Assay Feasibility** - conduct work to demonstrate the assay is able to detect the biomarkers US\$0.6 million – in progress; and
  - **Phase 3: System Prototype Delivery** – deliver a working prototype of the system - US\$3.7 million – not commenced

- ✓ **US\$10m IP Agreement payment received**
- ✓ **Phase 1 completed (US\$0.4m received)**
- ✓ **Phase 2 has now commenced**





# Product Update



# Henry Schein Distribution Agreements



- FebriDx is a rapid point-of-care respiratory test which delivers results after 10 minutes from a fingerstick blood sample.
- Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners.
- In February 2024, Lumos signed an agreement with Henry Schein, Inc. (Nasdaq: HSIC) to distribute FebriDx® in the United States.
  - Customer adoption has commenced and is ramping
- Post Reporting date: A new Henry Schein distribution agreement was executed for Australia and New Zealand on 4 July 2024, and an expansion agreement to sell into Belgium was enacted on 9 July 2024.
  - Ready to commence sales immediately into Australia/New Zealand for the current flu season.



# FebriDx Update

- **Reimbursement Amount: PLA Code update**
  - Positive momentum - CMA Panel presentation in June was well received, final decision expected Sept 2024
- **Partnerships**
  - 25 FebriDx partnerships in FY24: regional distributors and end-user customers
  - Immediate impact witnessed in university student health market
- **FebriDx customer resources delivered**
  - Validation panels
  - Proficiency sample protocol (API)
- **Clinical Trials**
  - To extend the label in the US for FebriDx from the current moderately-complex to include CLIA waived settings would greatly expand market in the US



# ViraDx Update

- **Distribution**
  - 19 ViraDx partnerships FY25
  - 3 new distribution agreements in Q4 FY24
- **Infection rates**
  - US summer: elevated acute respiratory infections (Covid)
  - Purchase orders have already provided a robust start to FY25
- **Stocking orders**
  - Full season v half season (due to timing of EUA) in FY24
  - Current partnerships can be leveraged
  - September/October timeframe for stocking orders



## Key Strategic Priorities

A horizontal bar composed of several colored segments: yellow, grey, blue, purple, light purple, dark purple, red, and orange.



# Key Strategic Priorities



**Focus on growing sales of our two in-market proprietary products, FebriDx and ViraDx**



**Building a sustainable and growing pipeline of commercial, revenue-generating projects for both development services and contract manufacturing**



**Deliver on milestones relating to the Hologic fFN Development Agreement with Hologic**



**Continue to seek regulatory clearances to market our point-of-care products, focusing sales and marketing efforts on markets where these products have secured clearances, as well as seeking new partnering opportunities for our products**



[lumosdiagnostics.com](http://lumosdiagnostics.com)